Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
NCT03399773
Recruiting
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and in some cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cells in the bone marrow, including normal blood-forming... Read More
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
04/09/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
Register for Updates
Optimizing PTCy Dose and Timing
NCT03983850
Recruiting
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of PTCy can have the same benefits. Based on encouraging results from the first part of the study, researchers now are investigating whether a lower dose of PTCy can allow other immunosuppression to be dec... Read More
Gender:
ALL
Ages:
Between 12 years and 120 years
Trial Updated:
04/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Register for Updates
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
NCT03710421
Recruiting
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can be engineered to kill multiple myeloma cells by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that allows them to recognize multiple myeloma cells. These en... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
NCT04231877
Recruiting
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Glofitamab is a monoclona... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Gray-Zone Lymphoma
Register for Updates
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Recruiting
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +15 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
NCT04530565
Recruiting
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +205 locations
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
NCT04959175
Recruiting
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and severity of GVHD. Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness. Such an approach is being used in an ongoing clinical study at the NIH with promising result... Read More
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
04/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Hematologic Neoplasms
Register for Updates
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184
Active Not Recruiting
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: City of Hope, Duarte, California +9 locations
Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT06083883
Recruiting
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Register for Updates
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
NCT02114229
Active Not Recruiting
This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with recurrent or refractory AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT will receive alisertib as part of age- and risk-adapted chemotherapy. Radiation therapy will be given to children ≥12 months of age. Patients with AT/RT and concurrent extra-CNS MRT are eligible. Alisertib will be administere... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/08/2025
Locations: Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California +8 locations
Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Register for Updates
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
NCT01659151
Active Not Recruiting
The purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body from viral infections, help other cells fight bacterial and fungal infections, produce antibodies, fight cancers, and coordinate the activities of other cells in the immune system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Metastatic Melanoma
Register for Updates
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Recruiting
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates